Skip Navigation


Brain Advance Access originally published online on February 2, 2005
Brain 2005 128(3):678-687; doi:10.1093/brain/awh399
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
128/3/678    most recent
awh399v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (41)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pauleit, D.
Right arrow Articles by Langen, K.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pauleit, D.
Right arrow Articles by Langen, K.-J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2005). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please e-mail: journal.permissions{at}oupjournals.org

O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas

Dirk Pauleit1,5, Frank Floeth6, Kurt Hamacher2,4, Markus J. Riemenschneider7, Guido Reifenberger7, Hans-Wilhelm Müller5, Karl Zilles3,4, Heinz H. Coenen2,4 and Karl-Josef Langen3,4

1 Clinic for Nuclear Medicine (KME), 2 Institute of Nuclear Chemistry (INC), 3 Institute of Medicine (IME) and 4 Brain Imaging Center West, Research Center Jülich, Jülich, 5 Department of Nuclear Medicine, 6 Department of Neurosurgery and 7 Department of Neuropathology, Heinrich Heine University, Düsseldorf, Germany

Correspondence to: Dirk Pauleit, Clinic for Nuclear Medicine (KME), Research Center Jülich, Leo-Brandt-Strasse; 52425 Jülich, Germany E-mail: pauleit{at}web.de

MRI is commonly used to determine the location and extent of cerebral gliomas. We investigated whether the diagnostic accuracy of MRI could be improved by the additional use of PET with the amino acid O-(2-[18F]fluoroethyl)-L-tyrosine (FET). In a prospective study, PET with FET and MRI was performed in 31 patients with suspected cerebral gliomas. PET and MRIs were co-registered and 52 neuronavigated tissue biopsies were taken from lesions with both abnormal MRI signal and increased FET uptake (match), as well as from areas with abnormal MR signal but normal FET uptake or vice versa (mismatch). Biopsy sites were labelled by intracerebral titanium pellets. The diagnostic performance for the identification of cellular tumour tissue was analysed for either MRI alone or MRI combined with FET PET using alternative free response receiver operating characteristic curves (ROCs). Histologically, 26 biopsy samples corresponded to cellular glioma tissue and 26 to peritumoral brain tissue. The diagnostic performance, as determined by the area under the ROC curve (Az), was Az = 0.80 for MRI alone and Az = 0.98 for the combined MRI and FET PET approach (P < 0.001). MRI yielded a sensitivity of 96% for the detection of tumour tissue but a specificity of only 53%, and combined use of MRI and FET PET yielded a sensitivity of 93% and a specificity of 94%. Combined use of MRI and FET PET in patients with cerebral gliomas significantly improves the identification of cellular glioma tissue and allows definite histological tumour diagnosis. Thus, our findings may have considerable impact on target selection for diagnostic biopsies as well as therapy planning.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNMHome page
C. Plathow and W. A. Weber
Tumor Cell Metabolism Imaging
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. Stadlbauer, O. Prante, C. Nimsky, E. Salomonowitz, M. Buchfelder, T. Kuwert, R. Linke, and O. Ganslandt
Metabolic Imaging of Cerebral Gliomas: Spatial Correlation of Changes in O-(2-18F-Fluoroethyl)-L-Tyrosine PET and Proton Magnetic Resonance Spectroscopic Imaging
J. Nucl. Med., May 1, 2008; 49(5): 721 - 729.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
F. W. Floeth, M. Sabel, G. Stoffels, D. Pauleit, K. Hamacher, H.-J. Steiger, and K.-J. Langen
Prognostic Value of 18F-Fluoroethyl-L-Tyrosine PET and MRI in Small Nonspecific Incidental Brain Lesions
J. Nucl. Med., May 1, 2008; 49(5): 730 - 737.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. Salber, G. Stoffels, D. Pauleit, A.-M. Oros-Peusquens, N. J. Shah, P. Klauth, K. Hamacher, H. H. Coenen, and K.-J. Langen
Differential Uptake of O-(2-18F-Fluoroethyl)-L-Tyrosine, L-3H-Methionine, and 3H-Deoxyglucose in Brain Abscesses
J. Nucl. Med., December 1, 2007; 48(12): 2056 - 2062.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Schiepers, W. Chen, T. Cloughesy, M. Dahlbom, and S.-C. Huang
18F-FDOPA Kinetics in Brain Tumors
J. Nucl. Med., October 1, 2007; 48(10): 1651 - 1661.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. Chen
Clinical Applications of PET in Brain Tumors
J. Nucl. Med., September 1, 2007; 48(9): 1468 - 1481.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
F. W. Floeth, D. Pauleit, M. Sabel, G. Stoffels, G. Reifenberger, M. J. Riemenschneider, P. Jansen, H. H. Coenen, H.-J. Steiger, and K.-J. Langen
Prognostic Value of O-(2-18F-Fluoroethyl)-L-Tyrosine PET and MRI in Low-Grade Glioma
J. Nucl. Med., April 1, 2007; 48(4): 519 - 527.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. T. Wyss, N. Spaeth, G. Biollaz, J. Pahnke, P. Alessi, E. Trachsel, V. Treyer, B. Weber, D. Neri, and A. Buck
Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 Gliomas and Correlation with 131I-SIP(L19), a Marker of Angiogenesis
J. Nucl. Med., April 1, 2007; 48(4): 608 - 614.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. Chen, D. H.S. Silverman, S. Delaloye, J. Czernin, N. Kamdar, W. Pope, N. Satyamurthy, C. Schiepers, and T. Cloughesy
18F-FDOPA PET Imaging of Brain Tumors: Comparison Study with 18F-FDG PET and Evaluation of Diagnostic Accuracy
J. Nucl. Med., June 1, 2006; 47(6): 904 - 911.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
F. W. Floeth, D. Pauleit, M. Sabel, G. Reifenberger, G. Stoffels, W. Stummer, F. Rommel, K. Hamacher, and K.-J. Langen
18F-FET PET Differentiation of Ring-Enhancing Brain Lesions
J. Nucl. Med., May 1, 2006; 47(5): 776 - 782.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
G. Popperl, F. W. Kreth, J. Herms, W. Koch, J. H. Mehrkens, F. J. Gildehaus, H. A. Kretzschmar, J. C. Tonn, and K. Tatsch
Analysis of 18F-FET PET for Grading of Recurrent Gliomas: Is Evaluation of Uptake Kinetics Superior to Standard Methods?
J. Nucl. Med., March 1, 2006; 47(3): 393 - 403.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. Pauleit, A. Zimmermann, G. Stoffels, D. Bauer, J. Risse, M. O. Fluss, K. Hamacher, H. H. Coenen, and K.-J. Langen
18F-FET PET Compared with 18F-FDG PET and CT in Patients with Head and Neck Cancer
J. Nucl. Med., February 1, 2006; 47(2): 256 - 261.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.